Ocugen, Inc.
Ocugen, Inc. (OCGN) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Malvern, United States and has 116 employees. The company is worth $264.61M. Revenue was $4.41M in fiscal 2025, up 8.8% from the year before. It reported a net loss of $67.85M. The share price is 71.4% below its 52-week high of $2.73. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $21.33M. In that quarter, 1 of them reduced the position. Over the last 30 days, company insiders sold $499.69K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -87.7% over 5Y.
today you would have $65.90▼ -93.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.35 | $0.81 | $0.57 | $1.30 | $4.55 | $1.83 | $0.52 | $5.28 | $123.00 | $100.20 | $210.00 | $660.00 | |
| P/S | 100.3x | 100.3x | 58.0x | 24.5x | 118.3x | — | 8004.7x | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CUVLClinuvel Pharmaceuticals Ltd | $5.24 | 11.6x | 1.4x | 0.76% | 13.21% | $264.3M |
| CTNMContineum Therapeutics, Inc. | $7.08 | — | 1.1x | 0.00% | -28.00% | $266.36M |
| INFUInfuSystem Holdings, Inc | $13.40 | 33.5x | 4.5x | 0.00% | 15.03% | $266.89M |
| NAUTNautilus Biotechnology, Inc. |
| — |
| — |
| — |
| P/B | 3.8x | — | 7.9x | 3.6x | 4.0x | 10.0x | 16.0x | 2.5x | — | 13.3x | 2.7x | 1.6x | 2.6x |
| EPS | — | — | -$0.26 | -$0.40 | -$0.30 | -$0.31 | -$1.46 | -$47.40 | -$59.40 | -$130.80 | -$145.20 | -$411.00 |
| Profit margin | -1537.41% | -1537.41% | -1333.02% | -1045.03% | -3488.91% | — | -50748.84% | — | — | — | — | — | — |
| ROE | -118.40% | — | -182.42% | -155.50% | -117.33% | -64.00% | -101.26% | -183.71% | — | -595.58% | -119.47% | -113.57% | -42.05% |
Median of the years shown; P/E years above 200x are left out.
| $2.06 |
| — |
| 2.0x |
| 0.00% |
| -36.21% |
| $262.15M |
| OSUROrasure Technologies Inc | $3.80 | — | 0.8x | 0.00% | -14.07% | $262.08M |
| PRLDPrelude Therapeutics Inc | $3.26 | — | 2.5x | 0.00% | -57.73% | $260.16M |